Update on COVID-19 Disease Severity Test

Genetic Technologies Provides Update on COVID-19 Disease Severity Test

Highlights

-Genetic Technologies has filed a provisional patent for its COVID-19 Severity Risk Test with the Patent Office in Australia

-The COVID-19 Severity Risk Test comprises a polygenic risk test (PRS) and assessment for clinical risk factors

-Genetic Technologies has completed the design and request for initial production of the SNP (Single Nucleotide Polymorphism) panel required to process the polygenic risk test portion of the COVID-19 Severity Risk Test from US-based Thermo Fisher Scientific

-Genetic Technologies has confirmed with major manufacturers that the COVID-19 Severity Risk Test, including a reagent and SNP panel, is capable of being rolled out on a large scale

-Discussions held with Centres for Medicare and Medicaid Services (CMS) and National Association of testing Authorities, Australia (“NATA”) for regulatory Approval for the COVID-19 Severity Risk Test in the United States and Australia

Genetic Technologies has filed a provisional patent for its COVID-19 Severity Risk Test with IP Australia (2020901739 – Methods of assessing risk developing a severe response to Coronavirus infection)

globenewswire.com/news-release/2020/07/15/2062531/0/en/Genetic-Technologies-Provides-Update-on-COVID-19-Disease-Severity-Test.html

Furthermore, the company has confirmed capacity to scale up production for a global-roll out of the COVID-19 test (reagent and SNP panel) with major manufacturers.

The Company's Australian facilities will have the capacity of producing up to 250,000 tests per year. The scale-up of manufacturing will require global distribution partnerships if COVID-19 Severity Risk Test is widely adopted.

GENE is in discussion with the respective regulatory authorities for approval of COVID-19 Severity Risk Test in the U.S. and Australia.

seekingalpha.com/news/3591386-genetic-technologiesplus-21-on-advancement-of-covidminus-19-severity-risk-test